ErythroMer
Life-threatening blood loss / Hemorrhagic shock
PreclinicalActive
Key Facts
Indication
Life-threatening blood loss / Hemorrhagic shock
Phase
Preclinical
Status
Active
Company
About KaloCyte
KaloCyte is pioneering a first-in-class, shelf-stable artificial red blood cell substitute called ErythroMer™, targeting the critical gap in transfusion medicine for pre-hospital and austere environments. Founded by experts in physiology, trauma care, and nanotechnology, the company has secured over $27 million in non-dilutive government grants and investor funding to advance its platform. As a BLUE KNIGHT™ company partnered with Johnson & Johnson Innovation and BARDA, KaloCyte is positioned to advance ErythroMer towards Investigational New Drug (IND)-enabling studies and first-in-human trials.
View full company profile